Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Depreciation & Amortization (CF) (2016 - 2025)

Cytosorbents (CTSO) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $364000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 4.96% year-over-year to $364000.0, compared with a TTM value of $1.5 million through Sep 2025, down 2.94%, and an annual FY2024 reading of $1.6 million, up 7.61% over the prior year.
  • Depreciation & Amortization (CF) was $364000.0 for Q3 2025 at Cytosorbents, down from $404497.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $407208.0 in Q3 2023 and bottomed at $123751.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $304229.9, with a median of $364000.0 recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) decreased 21.92% in 2021, then soared 91.11% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $214402.0 in 2021, then increased by 4.11% to $223214.0 in 2022, then skyrocketed by 75.29% to $391269.0 in 2023, then fell by 0.55% to $389104.0 in 2024, then fell by 6.45% to $364000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CTSO at $364000.0 in Q3 2025, $404497.0 in Q2 2025, and $368503.0 in Q1 2025.